Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide

Andersen, Kenneth Geving; Jensen, Maj‐Britt; Kehlet, Henrik; Gärtner, Rune; Eckhoff, Lise; Kroman, Niels

doi:10.3109/0284186x.2012.692884

Cited by 41 publications

(47 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results agree well with those of Osmani et al [7] reporting that 29/56 patients (52%) suffered from PN 1-13 years after treatment with docetaxel and Andersen et al reporting PN from 23% in the hands to 32% in the feet at a median of 34 months following adjuvant docetaxel [6]. This study reported only whether PN was present but not the severity of symptoms.…”

Section: Discussionsupporting

confidence: 95%

“…This is in agreement with two other studies also demonstrating that persistent PN was associated with age older than 50-60 years [6,16] and that grade of PN during treatment was associated with a higher risk of persistent PN [16]. The latter finding underlines the importance of delaying or reducing dose in patients with grade 2, 3 and 4 PN during treatment.…”

Section: Discussionsupporting

confidence: 92%

“…In a Danish study, Andersen et al reported symmetric peripheral sensory disturbances in the hands of 363/1596 (23%) and in the feet of 506/1596 (32%), at a median of 34 months following adjuvant docetaxel [6]. In a smaller study of persistent PN, 34/56 patients (61%) developed PN during docetaxel treatment and 29/56 (52%) of these still complained about PN 1-13 years after treatment cessation [7].…”

Section: Introductionmentioning

confidence: 94%

See 2 more Smart Citations

Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors

Eckhoff¹,

Knoop²,

Jensen³

et al. 2015

European Journal of Cancer

126

120

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 95%

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors

Eckhoff¹,

Knoop²,

Jensen³

et al. 2015

European Journal of Cancer

126

120

View full text Add to dashboard Cite

“…36,39,43,50,53,55,56 However, the results from these studies were consistent with the results from studies amenable to pooling. We used the IASP criteria for the definition of persistent pain in this review; however, 14 of the included studies did not report whether their assessment of persistent postsurgical pain excluded other causes of pain; 26,[33][34][35][36]43,45,47,48,50,51,54,56,58 as such, they may have overestimated the prevalence of persistent pain.…”

Section: Strengths and Limitationsmentioning

confidence: 99%

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Wang

Guyatt

Kennedy

et al. 2016

CMAJ

242

239

View full text Add to dashboard Cite

D espite a 10-year survival rate of 83%, 1,2 between 25% and 60% of surviving patients who have undergone surgery for breast cancer experience persistent postsurgical pain, [3][4][5][6][7][8][9] which is associated with reduced quality of life and functional impairment. [10][11][12][13] Systematic reviews summarizing proposed risk factors for persistent pain after breast cancer surgery -including demographic, intraoperative and postoperative factors -have had several limitations, including outdated searches, inadequate attention to risk-of-bias assessment, lack of statistical pooling of measures of association and failure to evaluate the quality of evidence.5,10-14 We conducted a systematic review and meta-analysis of observational studies to identify risk factors for persistent pain after breast cancer surgery, addressing the limitations of previous reviews. MethodsWe completed our systematic review in accordance with the MOOSE statement 15 and registered our protocol with PROSPERO (registration CRD42014013338). Background: Persistent pain after breast cancer surgery affects up to 60% of patients. Early identification of those at higher risk could help inform optimal management. We conducted a systematic review and meta-analysis of observational studies to explore factors associated with persistent pain among women who have undergone surgery for breast cancer. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

show abstract

“…148 Despite the logical assumption that the use of adjuvant chemotherapy or radiotherapy would potentiate the development of PPSP, multiple studies have failed to definitively show an association. 134,149 Nevertheless, some chemotherapy is associated with an increased risk of peripheral neuropathy 150 and work in animal models of PPSP have demonstrated a role for the TRPV1 channel (whose expression is increased in CIPN) in the development of cutaneous hypersensitivity following surgery. 151 …”

Section: Risk Factorsmentioning

confidence: 99%

Pain in cancer survivors

Brown

Ramirez

Farquhar-Smith

2014

British Journal of Pain

View full text Add to dashboard Cite

Cancer and its treatment exert a heavy psychological and physical toll. Of the myriad symptoms which result, pain is common, encountered in between 30% and 60% of cancer survivors. Pain in cancer survivors is a major and growing problem, impeding the recovery and rehabilitation of patients who have beaten cancer and negatively impacting on cancer patients' quality of life, work prospects and mental health. Persistent pain in cancer survivors remains challenging to treat successfully. Pain can arise both due to the underlying disease and the various treatments the patient has been subjected to. Chemotherapy causes painful chemotherapy-induced peripheral neuropathy (CIPN), radiotherapy can produce late effect radiation toxicity and surgery may lead to the development of persistent post-surgical pain syndromes. This review explores a selection of the common causes of persistent pain in cancer survivors, detailing our current understanding of the pathophysiology and outlining both the clinical manifestations of individual pain states and the treatment options available.

show abstract

Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide

Abstract: Docetaxcel as adjuvant treatment for breast cancer does not increase the risk of PPBCT, sensory disturbances in the surgical area or functional impairment, but increase risk for peripheral sensory disturbances.

Cited by 41 publications

References 21 publications

Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors

Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Pain in cancer survivors

Contact Info

Product

Resources

About